Identification of an orally active small-molecule PTHR1 agonist for the treatment of hypoparathyroidism
Citations Over TimeTop 10% of 2016 papers
Abstract
Parathyroid hormone (PTH) is essential for calcium homeostasis and its action is mediated by the PTH type 1 receptor (PTHR1), a class B G-protein-coupled receptor. Hypoparathyroidism and osteoporosis can be treated with PTH injections; however, no orally effective PTH analogue is available. Here we show that PCO371 is a novel, orally active small molecule that acts as a full agonist of PTHR1. PCO371 does not affect the PTH type 2 receptor (PTHR2), and analysis using PTHR1-PTHR2 chimeric receptors indicated that Proline 415 of PTHR1 is critical for PCO371-mediated PTHR1 activation. Oral administration of PCO371 to osteopenic rats provokes a significant increase in bone turnover with limited increase in bone mass. In hypocalcemic rats, PCO371 restores serum calcium levels without increasing urinary calcium, and with stronger and longer-lasting effects than PTH injections. These results strongly suggest that PCO371 can provide a new treatment option for PTH-related disorders, including hypoparathyroidism.
Related Papers
- → Activating Antibodies to the Calcium-Sensing Receptor in Two Patients with Autoimmune Hypoparathyroidism(2004)142 cited
- → Anti-Parathyroid and Anti-Calcium Sensing Receptor Antibodies in Autoimmune Hypoparathyroidism(2009)99 cited
- → Autosomal Dominant Hypocalcemia Caused by an Activating Mutation of the Calcium-Sensing Receptor Gene: The First Case Report in Korea(2010)7 cited
- [Pseudohypoparathyroidism. Disease of the second messenger].(1976)
- → Hypoparathyroidism(2017)